Celldex Therapeutics (NASDAQ:CLDX) Earns Overweight Rating from Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued on Thursday,Benzinga reports. They currently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 149.91% from the stock’s current price.

A number of other equities analysts have also commented on the company. Citigroup initiated coverage on Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Finally, The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Trading Up 4.0 %

NASDAQ CLDX opened at $26.81 on Thursday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -10.43 and a beta of 1.57. Celldex Therapeutics has a 1-year low of $22.93 and a 1-year high of $53.18. The company has a 50 day moving average of $26.12 and a 200-day moving average of $32.70.

Insider Buying and Selling

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds have recently added to or reduced their stakes in CLDX. Wellington Management Group LLP increased its stake in shares of Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Novo Holdings A S acquired a new position in Celldex Therapeutics during the second quarter valued at approximately $31,458,000. Point72 Asset Management L.P. increased its stake in Celldex Therapeutics by 51.0% in the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after purchasing an additional 654,194 shares in the last quarter. Marshall Wace LLP raised its holdings in Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after purchasing an additional 479,068 shares during the period. Finally, Jennison Associates LLC raised its holdings in Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after purchasing an additional 321,325 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.